More than 95% of newly developed anti-cancer drugs fail due a lack of efficacy in patients. Calico Biosystems by testing drugs directly in patient tumors reliably predicts drug efficacy in patients.
Current Status
Our customers are drug developers in oncology: pharma, biotechs and AI-powered drug developers. In 4 months we have generated 30 sales leads, obatained 2 LOI and are negociating 3 deals.
Our objective for the first year (Mid-2024 to mid-2025) is to show proof of commercialization by selling 2 products (CaliPower) and making 0.7-1.2M revenues.
We wish to establish strategic partnerships to grow our business and are in advanced stage of discussions with an EU CRO and a global AI company.
Problem or Opportunity
Calico Biosystems addresses the critical issue of the poor efficacy of anti-cancer drugs in patients. Cancer is a leading cause of death worldwide. Each year, pharma and biotech companies develop 8,000 new anti-cancer drugs, each costing 1B USD. More than 95% of the drugs fail to reach FDA approval, mostly because of a lack of efficacy. The causes mainly reside in the artificial models used in the pre-clinical testing that fail to recapitulate the complexity of patients' tumors and translate into clinical benefit for only 10% of cancer patients treated with approved drugs.
Solution (product or service)
Calico Biosystems is the only platform that tests drugs directly on patient tumors and reliably predicts drug efficacy in patients. Further, our unique digital solution simulates and predicts the outcome of any combination of treatments and identifies the most potent combinations of drugs.
Products
1) CaliPower: MSP and lead product, measures experimentally the efficacy of drugs in intact patient tumors, validated in 7 studies and more than 250 patient tumors.
2) CaliPredict simulates and predicts the most effective combinations of therapies through computational modeling.
Business model
We are a service provider with two main revenue streams: First we sell our products to our customers (mostly biotech and AI companies), and, second, we establish long-term deals with large pharma coporations. Thanks to our innovation, we de-risk clinical testing and shave the costs of drug development by 43%. Large pharma traction: 1 LOI obtained and advanced discussion with one additional large pharma (both in the top 10 worldwide).
